75 related articles for article (PubMed ID: 9815795)
1. Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin.
Zheng H; Fink D; Howell SB
Clin Cancer Res; 1997 Jul; 3(7):1157-65. PubMed ID: 9815795
[TBL] [Abstract][Full Text] [Related]
2. Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia.
Fulco RA; Vannozzi M; Collecchi P; Merlo F; Parodi B; Civalleri D; Esposito M
Anticancer Res; 1990; 10(6):1603-10. PubMed ID: 2285232
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
4. Polymer chemotherapy for head and neck cancer.
Shikani AH; Domb AJ
Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
[TBL] [Abstract][Full Text] [Related]
5. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.
Howell SB; Taetle R
Cancer Treat Rep; 1980; 64(4-5):611-6. PubMed ID: 7191778
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion.
Andrews PA; Murphy MP; Howell SB
Mol Pharmacol; 1986 Dec; 30(6):643-50. PubMed ID: 3785141
[TBL] [Abstract][Full Text] [Related]
7. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
8. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
9. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells.
Lin X; Okuda T; Trang J; Howell SB
Mol Pharmacol; 2006 May; 69(5):1748-54. PubMed ID: 16495473
[TBL] [Abstract][Full Text] [Related]
10. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
11. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.
Shen DW; Goldenberg S; Pastan I; Gottesman MM
J Cell Physiol; 2000 Apr; 183(1):108-16. PubMed ID: 10699972
[TBL] [Abstract][Full Text] [Related]
12. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines.
Kröning R; Lichtenstein AK; Nagami GT
Cancer Chemother Pharmacol; 2000; 45(1):43-9. PubMed ID: 10647500
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model.
Chen FA; Kuriakose MA; Zhou MX; DeLacure MD; Dunn RL
Head Neck; 2003 Jul; 25(7):554-60. PubMed ID: 12808659
[TBL] [Abstract][Full Text] [Related]
15. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
16. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
17. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
18. [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
Hu S; Hu CP; Liang CH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1493-8. PubMed ID: 16061030
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
Holzer AK; Katano K; Klomp LW; Howell SB
Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]